Differential activation of migration by hypoxia in keratinocytes isolated from donors of increasing age: implication for chronic wounds in the elderly.
Chronic wound healing conditions are often observed in elderly patients with poor tissue oxygenation. Impaired re-epithelialization is a hallmark of these wounds, which is seen in both clinical studies and in our animal models of impaired healing. To investigate the pathogenic mechanism of chronic wounds, we studied the effect of hypoxia on migration of keratinocytes isolated from human donors of increasing age. Keratinocytes from elderly donors had depressed migratory activity when exposed to hypoxia, as opposed to an increase in migration in young cells. Analysis of underlying biochemical changes demonstrated a differential activation of matrix metalloproteinases by hypoxia in keratinocytes isolated from the young and the old. Matrix metalloproteinases-1 and -9 and tissue inhibitor of matrix metalloproteinase-1 were strongly upregulated by hypoxia in young cells, whereas no induction was observed in aged cells. Furthermore, transforming growth factor-beta 1 signaling appears to be involved in the keratinocyte differential response to hypoxia, as transforming growth factor-beta type I receptor was upregulated by hypoxia in young cells, while there was no induction in aged cells. Transforming growth factor-beta neutralizing reagents blocked hypoxia-induced matrix metalloproteinase-1, matrix metalloproteinase-9 expression, and hypoxia-induced cell migration as well. Our results suggest that an age-related decrease in response to hypoxia plays a crucial part in the pathogenesis of retarded re-epithelialization in wound.
Xia
Y P
YP
Division of Plastic Surgery and Reconstructive Surgery, Department of Surgery, School of Medicine, North-western University, Chicago, Illinois 60611-3042, USA.
Zhao
Y
Y
Tyrone
J W
JW
Chen
A
A
Mustoe
T A
TA
D000328:Adult; D000368:Aged; D000375:Aging / Q000502:physiology*; D001706:Biopsy; D002465:Cell Movement; D002908:Chronic Disease; D006801:Humans; D000860:Hypoxia / Q000378:metabolism / Q000503:physiopathology*; D015603:Keratinocytes / Q000166:cytology*; D020781:Matrix Metalloproteinase 1 / Q000096:biosynthesis; D020780:Matrix Metalloproteinase 9 / Q000096:biosynthesis; D008666:Metalloendopeptidases / Q000096:biosynthesis / Q000494:pharmacology; D008875:Middle Aged; D018125:Receptors, Transforming Growth Factor beta / Q000096:biosynthesis; D012867:Skin / Q000473:pathology; D019714:Tissue Inhibitor of Metalloproteinases / Q000494:pharmacology; D016212:Transforming Growth Factor beta / Q000494:pharmacology; D014945:Wound Healing / Q000502:physiology; D014947:Wounds and Injuries / Q000503:physiopathology
D018125:Receptors, Transforming Growth Factor beta; D019714:Tissue Inhibitor of Metalloproteinases; D016212:Transforming Growth Factor beta; D008666:Metalloendopeptidases; D020780:Matrix Metalloproteinase 9; D020781:Matrix Metalloproteinase 1